{"filing":{"accession_number":"0001193125-26-399378","cik":"0002044725","ticker":"EVMN","company_name":"Evommune, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"evmn-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/evmn-20260923.htm"},"events":[{"id":34575,"run_id":31820,"accession_number":"0001193125-26-399378","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Evommune announced a late-breaker oral presentation of Phase 2a clinical trial data for EVO301 in atopic dermatitis at the EADV Congress. This is a material clinical development milestone for a clinical-stage biotech company, as positive Phase 2a data and conference presentation represent significant progress in the drug development pipeline. The disclosure emphasizes \"positive top-line data\" and advancement toward Phase 2b studies, which would affect investor assessment of the company's pipeline value and commercial prospects. This is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38333,"accession_number":"0001193125-26-399378","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced a late-breaker oral presentation of Phase 2a clinical trial data for EVO301 in atopic dermatitis at the EADV Congress. This is a material clinical development milestone for a clinical-stage biotech company, as positive Phase 2a data and conference presentation represent significant progress in the drug development pipeline. The disclosure emphasizes \"positive top-line data\" and advancement toward Phase 2b studies, which would affect investor assessment of the company's pipeline value and commercial prospects. This is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:09:23.802525+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38333,"accession_number":"0001193125-26-399378","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced a late-breaker oral presentation of Phase 2a clinical trial data for EVO301 in atopic dermatitis at the EADV Congress. This is a material clinical development milestone for a clinical-stage biotech company, as positive Phase 2a data and conference presentation represent significant progress in the drug development pipeline. The disclosure emphasizes \"positive top-line data\" and advancement toward Phase 2b studies, which would affect investor assessment of the company's pipeline value and commercial prospects. This is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:09:23.802525+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-09-23"}]}